A Study of TL-925 for the Treatment of Allergic Conjunctivitis
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled
study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to
receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen
challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.